{
  "docId": "019de070-5bad-7209-9a4b-c2388bb12878",
  "docSlug": "45a794600ccc29f3eaf009a5452211e7",
  "documentTitle": "Codiak | IPO Presentation Deck | 36 slides",
  "authorId": "codiak",
  "authorName": "Codiak",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 36,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "The slide uses a 'Before/After' or 'Problem/Solution' structure. It includes three distinct charts showing gene expression efficiency, ocular expression, and loading enhancement.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-5bad-7209-9a4b-c2388bb12878/30",
  "deckHref": "/decks/019de070-5bad-7209-9a4b-c2388bb12878",
  "deckJsonHref": "/decks/019de070-5bad-7209-9a4b-c2388bb12878.json",
  "deckAnchorHref": "/decks/019de070-5bad-7209-9a4b-c2388bb12878#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.15,
        "x": 0.6,
        "y": 0.65
      },
      "kind": "chart",
      "text": "Ocular engEx-AAV Gene Expression within Retinal Cells",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4f8bbeb3-925f-4b0b-8b2f-6f0b3300d2a9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.15,
        "x": 0.78,
        "y": 0.65
      },
      "kind": "chart",
      "text": "Engineering enhanced engEx-AAV loading",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8b96aa3b-ae04-44c4-8cdb-8478d9cf2ee3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.18,
        "x": 0.4,
        "y": 0.65
      },
      "kind": "chart",
      "text": "High efficiency, neutralization-resistant gene expression",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cf2400fc-c4c1-4d5e-83fa-b645bab131b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.08,
        "x": 0.42,
        "y": 0.22
      },
      "kind": "image",
      "text": "engEx-AAV 25nm",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6718cd6a-2ce2-4b41-aa26-e8f5ae7d48c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.1,
        "x": 0.15,
        "y": 0.25
      },
      "kind": "image",
      "text": "Free AAV 25nm",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8cca4ce1-6073-46c1-b6de-d77783503bda",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.55,
        "x": 0.4,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "engEx-AAV SOLUTION: Targeted, Repeat Dosing Regardless of AAV Exposure. Exosome shielded AAV + Compartmental dosing + Engineered exosome cellular tropism. Improved intrinsic AAV activity, Manufacturing advantages / COGS.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "26029d8a-0e3b-4748-8309-27be664b2336",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.05,
        "y": 0.42
      },
      "kind": "paragraph",
      "text": "CHALLENGES: High Dose of AAV Associated with Toxicity. Neutralizing anti-AAV antibodies (nAbs), Inadequate or fading gene expression, Limited tropism of effective AAV-vectors, High dose AAV associated with toxicity.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "de879ed7-ab0d-48c8-9fc5-8f05cf917c7a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "engEx-AAV™: Seeking a Solution for Non-Viral Delivery of Gene Therapy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1260f9ea-f506-4b3e-b064-1656d01b4848",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "e1bc317d-8c85-4e43-be33-f98c7f0e8a52",
      "evidence": "CHALLENGES: High Dose of AAV Associated with Toxicity. Neutralizing anti-AAV antibodies (nAbs), Inadequate or fading gene expression, Limited tropism of effective AAV-vectors, High dose AAV associate",
      "confidence": 0.7
    },
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "7d54bbfc-9504-4214-b612-ba4054d40b66",
      "evidence": "chart/line: High efficiency, neutralization-resistant gene expression",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "before-after-bridge",
      "slug": null,
      "matchId": "ef9b39ca-2272-4df1-877d-f5455ed6a0ad",
      "evidence": "Contrasts current AAV challenges with the engEx-AAV solution.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 35,
      "from": 16,
      "beatId": "87a4caff-9c60-44c7-b0ac-0079e1a8e9eb",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Roadmap",
      "beatSlug": null,
      "evidence": "Slides 16-35 outline Codiak's pipeline, clinical programs, and future plans",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}